BRAINSTORM CELL THERAPEUTICS INC. - 10-Q filing on 2022-05-16

STOCK CAPITAL (Tables)

3 Months Ended

Mar. 31, 2022

Summary of the Company's option activity

NOTE 7 – STOCK CAPITAL (Cont.):

A summary of the Company’s option activity related to options to employees and directors, and related information as of March 31, 2022, is as follows:


	For the Three months ended
	March 31, 2022
		Weighted
		average	Aggregate
	Amount of	exercise	intrinsic
	options *	price	value
		$	$
Outstanding at December 31, 2021	1,310,417	4.1734
Granted	26,400	3.0400
Outstanding at March 31, 2022	1,336,817	4.091	—
Exercisable at March 31, 2022	1,026.609	3.0351	333,549

* Represents Employee Stock Options only (not including RSUs).

Schedule of compensation expense for restricted stock is based on fair market value at the grant date


			Weighted Average
			Remaining
	Number of Shares	Weighted Average	Contractual
	of Restricted	Grant Date Fair	Term
	Stock	Value	(Years)
Nonvested as of December 31, 2021	272,596	5.49	1.23
Granted	39,767	3.06
Vested	41,691	4.59
Nonvested as of March 31, 2022	270,672	5.28	1.33

Schedule of total stock-based compensation expense

The total stock-based compensation expense, related to shares, options and warrants granted to employees, directors and service providers was comprised, at each period, as follows:


	Three months ended
	March 31,
	2022		2021
Research and development	$	147	$	(65)
General and administrative		358		355
Total stock-based compensation expense	$	505	$	290